Reviewing Sanara MedTech (NASDAQ:SMTI) & Nova Eye Medical (OTCMKTS:ELXMF)

Sanara MedTech (NASDAQ:SMTI) and Nova Eye Medical (OTCMKTS:ELXMF) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, risk, earnings, profitability, valuation, dividends and institutional ownership.

Institutional and Insider Ownership

8.1% of Sanara MedTech shares are held by institutional investors. Comparatively, 12.4% of Nova Eye Medical shares are held by institutional investors. 42.0% of Sanara MedTech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Sanara MedTech and Nova Eye Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sanara MedTech	-29.15%	31.56%	2.82%
Nova Eye Medical	N/A	N/A	N/A

Analyst Ratings

This is a summary of current ratings and target prices for Sanara MedTech and Nova Eye Medical, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sanara MedTech	1	4	0	0	1.80
Nova Eye Medical	0	0	0	0	0.00

Sanara MedTech presently has a consensus price target of $35.00, indicating a potential upside of 1.95%. Given Sanara MedTech’s stronger consensus rating and higher probable upside, equities analysts plainly believe Sanara MedTech is more favorable than Nova Eye Medical.

Earnings & Valuation

This table compares Sanara MedTech and Nova Eye Medical”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sanara MedTech	$103.12 million	3.05	-$37.56 million	($3.77)	-9.11
Nova Eye Medical	N/A	N/A	N/A	$0.01	1.96

Nova Eye Medical has lower revenue, but higher earnings than Sanara MedTech. Sanara MedTech is trading at a lower price-to-earnings ratio than Nova Eye Medical, indicating that it is currently the more affordable of the two stocks.

Summary

Sanara MedTech beats Nova Eye Medical on 6 of the 10 factors compared between the two stocks.

About Sanara MedTech

Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. It also provides BIAKOS Antimicrobial Skin and Wound Cleanser, a patented product that contains synergistic ingredients that have been shown to impact mature biofilm microbes; BIAKOS Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing that helps against planktonic microbes, as well as immature and mature biofilms; and BIAKOS Antimicrobial Skin and Wound Irrigation Solution. In addition, it develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement; and VIM Amnion Matrix, a homologous wound covering product. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.

About Nova Eye Medical

Nova Eye Medical Limited designs, develops, manufactures, markets, and sells surgical devices for the treatment of glaucoma in Australia, the United States, Europe, the Asia Pacific, and internationally. It offers iTrack, a glaucoma surgical device to reduce intraocular pressure in adult patients with open-angle glaucoma; iTrack Advance, a canaloplasty microcatheter; Molteno3, a glaucoma drainage device to treat patients with severe or complex glaucoma; and 2RT, a proprietary laser technology to treat patients in early/intermediate age-related macular degeneration. The company was formerly known as Ellex Medical Lasers Limited and changed its name to Nova Eye Medical Limited in July 2020. Nova Eye Medical Limited was incorporated in 1970 and is headquartered in Kent Town, Australia.